MYC and neoplasm: We observed an increase of Vimentin (Vim) mesenchymal marker and a decrease in E-cadherin (Cdh1) epithelial marker in Myc-R26Met compared with Alb-R26Met tumours (Fig. 3G, H), indicating a more mesenchymal phenotype for Myc-R26Met, which has been associated with aggressiveness, poor prognosis and resistance to drugs currently used in the clinics [41, 42].